Regulus Therapeutics Inc. (NASDAQ:RGLS)‘s stock had its “ourperform” rating reissued by stock analysts at Wedbush in a research report issued to clients and investors on Monday. They currently have a $4.00 target price on the biopharmaceutical company’s stock. Wedbush’s target price would suggest a potential upside of 329.65% from the company’s current price.

RGLS has been the subject of a number of other reports. ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Chardan Capital decreased their price objective on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Wednesday, July 12th. BMO Capital Markets restated a “hold” rating on shares of Regulus Therapeutics in a research note on Monday, May 15th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. Regulus Therapeutics has an average rating of “Hold” and an average target price of $3.58.

Regulus Therapeutics (NASDAQ:RGLS) traded up 3.11% during trading on Monday, reaching $0.96. The company’s stock had a trading volume of 75,723 shares. The stock has a 50-day moving average of $1.00 and a 200 day moving average of $1.35. The firm’s market capitalization is $51.05 million. Regulus Therapeutics has a one year low of $0.86 and a one year high of $3.82.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.10. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. On average, equities research analysts predict that Regulus Therapeutics will post ($1.06) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/regulus-therapeutics-inc-rgls-earns-ourperform-rating-from-wedbush.html.

In related news, Director William H. Rastetter bought 274,725 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, for a total transaction of $249,999.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Daniel R. Chevallard bought 54,945 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was bought at an average price of $0.91 per share, for a total transaction of $49,999.95. Following the purchase, the chief financial officer now owns 59,415 shares in the company, valued at approximately $54,067.65. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 549,450 shares of company stock worth $500,000. Company insiders own 4.80% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Tudor Investment Corp Et Al acquired a new stake in Regulus Therapeutics during the fourth quarter valued at $105,000. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 43.4% in the second quarter. Wedbush Securities Inc. now owns 47,061 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 14,246 shares during the period. Teachers Advisors LLC raised its stake in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 9,804 shares during the period. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at $164,000. Finally, Swiss National Bank raised its stake in Regulus Therapeutics by 9.2% in the second quarter. Swiss National Bank now owns 58,200 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 4,900 shares during the period. Institutional investors and hedge funds own 21.09% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.